UPSTREAM BIO, INC. Increase (Decrease) in Accounts and Notes Receivable
UPSTREAM BIO, INC. (UPB) reported Increase (Decrease) in Accounts and Notes Receivable of $104.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable · last filed 2026-08-11
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for the quarter ending 2026-06-30 was -$262.00K, a 170.62% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for the quarter ending 2026-03-31 was $366.00K.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for the quarter ending 2025-12-31 was -$15.00K, a 350.00% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for the quarter ending 2025-09-30 was -$254.00K, a 361.86% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for fiscal 2025 was $55.00K, a 89.32% decline from fiscal 2024.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for fiscal 2024 was $515.00K.
- UPSTREAM BIO, INC. increase (decrease) in accounts and notes receivable for fiscal 2023 was -$314.00K.
| Period end | Increase (Decrease) in Accounts and Notes Receivable 3 month | Increase (Decrease) in Accounts and Notes Receivable 6 month | Increase (Decrease) in Accounts and Notes Receivable 9 month | Increase (Decrease) in Accounts and Notes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $104.00K 10-Q · filed 2026-08-11 | $89.00K derived: sum of 3 quarters · filed 2026-08-11 | -$165.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $366.00K 10-Q · filed 2026-05-13 | $351.00K derived: sum of 2 quarters · filed 2026-05-13 | $97.00K derived: sum of 3 quarters · filed 2026-05-13 | $468.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$269.00K derived: sum of 2 quarters · filed 2026-03-26 | $102.00K derived: sum of 3 quarters · filed 2026-08-11 | $55.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $117.00K derived: sum of 2 quarters · filed 2026-08-11 | $70.00K 10-Q · filed 2025-11-05 | $76.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $324.00K 10-Q · filed 2026-08-11 | $330.00K derived: sum of 3 quarters · filed 2026-08-11 | $427.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$47.00K 10-Q · filed 2026-05-13 | -$41.00K derived: sum of 2 quarters · filed 2026-05-13 | $56.00K derived: sum of 3 quarters · filed 2026-05-13 | -$172.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $103.00K derived: sum of 2 quarters · filed 2026-03-26 | -$125.00K derived: sum of 3 quarters · filed 2026-03-26 | $515.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$131.00K derived: sum of 2 quarters · filed 2025-11-05 | $509.00K 10-Q · filed 2025-11-05 | $342.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $412.00K 10-Q · filed 2025-08-06 | $245.00K derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $640.00K 10-Q · filed 2025-05-06 | $473.00K derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$314.00K 10-K · filed 2025-03-12 | ||
| 2023-09-30 | -$147.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |